OS Therapies, Inc. (OSTX) Press Releases https://ir.ostherapies.com/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/ostherapies/files/theme/images/logo-sm-2x.png OS Therapies, Inc. Logo Equisolve Investor Relations Suite <![CDATA[OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer]]> https://ir.ostherapies.com/news-events/press-releases/detail/131/os-therapies-appoints-kerry-clem-as-chief-commercial Thu, 01 Oct 26 08:30:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/131/os-therapies-appoints-kerry-clem-as-chief-commercial <![CDATA[OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)]]> https://ir.ostherapies.com/news-events/press-releases/detail/130/os-therapies-announces-brand-name-herlystic-approved-by Thu, 24 Sep 26 08:22:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/130/os-therapies-announces-brand-name-herlystic-approved-by <![CDATA[OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis]]> https://ir.ostherapies.com/news-events/press-releases/detail/129/os-therapies-completes-fda-type-c-statistical-methods Mon, 21 Sep 26 06:30:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/129/os-therapies-completes-fda-type-c-statistical-methods <![CDATA[OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program]]> https://ir.ostherapies.com/news-events/press-releases/detail/128/os-therapies-achieves-incremental-alignment-with-fda-and Thu, 17 Sep 26 06:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/128/os-therapies-achieves-incremental-alignment-with-fda-and <![CDATA[OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing]]> https://ir.ostherapies.com/news-events/press-releases/detail/127/os-therapies-announces-full-alignment-with-uk-mhra-and-eu Tue, 15 Sep 26 07:46:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/127/os-therapies-announces-full-alignment-with-uk-mhra-and-eu <![CDATA[OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial]]> https://ir.ostherapies.com/news-events/press-releases/detail/126/os-therapies-achieves-statistically-significant-benefit-for Tue, 08 Sep 26 06:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/126/os-therapies-achieves-statistically-significant-benefit-for <![CDATA[OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance]]> https://ir.ostherapies.com/news-events/press-releases/detail/125/os-therapies-provides-ost-her2-metastatic-osteosarcoma Wed, 02 Sep 26 07:20:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/125/os-therapies-provides-ost-her2-metastatic-osteosarcoma <![CDATA[OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates]]> https://ir.ostherapies.com/news-events/press-releases/detail/124/os-therapies-reports-second-quarter-2026-financials-and Mon, 17 Aug 26 07:40:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/124/os-therapies-reports-second-quarter-2026-financials-and <![CDATA[OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma]]> https://ir.ostherapies.com/news-events/press-releases/detail/123/os-therapies-granted-u-s-fda-type-c-statistical-methods Thu, 13 Aug 26 08:45:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/123/os-therapies-granted-u-s-fda-type-c-statistical-methods <![CDATA[OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program]]> https://ir.ostherapies.com/news-events/press-releases/detail/122/os-therapies-accepts-new-fda-meeting-request-to-review Wed, 08 Jul 26 09:00:00 -0400 https://ir.ostherapies.com/news-events/press-releases/detail/122/os-therapies-accepts-new-fda-meeting-request-to-review